HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Draws The Line On Wrinkle Reduction Claims In Warning Letter

This article was originally published in The Rose Sheet

Executive Summary

Wrinkle reduction claims for University Medical Products' Face Lift Collagen 5 products reflect changes to the structure or function of the body, necessitating new drug approval for the products, FDA states in a 1warning letter recently posted to its Web site

You may also be interested in...



Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says

Klein-Becker's signature statement for StriVectin-SD anti-aging cream - "Better than Botox?" - constitutes a structure/function claim that would require the product to be regulated as a drug, the agency states in a 1warning letter recently posted on its Web site

Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says

Klein-Becker's signature statement for StriVectin-SD anti-aging cream - "Better than Botox?" - constitutes a structure/function claim that would require the product to be regulated as a drug, the agency states in a 1warning letter recently posted on its Web site

NAD Takes Initiative In Reviews Of Anti-Aging, Cellulite Claims In 2004

Skin care marketers are likely to step up challenges to competitors' ad claims regarding wrinkle reduction as the market for anti-aging products grows, according to David Mallen, Assistant Director and Senior Attorney at the National Advertising Division of the Council of Better Business Bureaus

Related Content

UsernamePublicRestriction

Register

RS011988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel